Schneider et al developed a scoring system can be used to estimate survival in women with advanced ovarian cancer. This uses 4 parameters determined at the time of presentation or initial surgery. The study was performed at Assaf Harofeh Medical Center in Israel.
Patient selection: Patients with Stage III or IV ovarian cancer were evaluated.
Parameters:
(1) gravidity
(2) tumor stage
(3) serum LDH in U/L
(4) serum CA-125 in U/mL
Parameter |
Finding |
Points |
---|---|---|
gravidity |
<= 2 pregnancies |
2 |
|
> 2 pregnancies |
1 |
tumor stage |
IIIA or IIIB |
1 |
|
IIIC |
2 |
|
IV |
3 |
LDH |
<= 240 U/L |
1 |
|
> 240 and <= 600 U/L |
4 |
|
> 600 U/L |
6 |
CA-125 |
<= 100 U/mL |
1 |
|
> 100 U/mL |
4 |
score =
= SUM(points for the 4 parameters)
Interpretation:
• minimum score: 4
• maximum score: 15
• The higher the score, the lower the survival.
Score |
LOG10 |
LOG10 - LOG10(4) |
Estimated Survival in Months |
---|---|---|---|
4 |
0.602 |
0 |
63 |
5 |
0.699 |
0.097 |
55 |
6 |
0.778 |
0.176 |
45 |
7 |
0.845 |
0.243 |
38 |
8 |
0.903 |
0.301 |
33 |
9 |
0.954 |
0.352 |
26 |
10 |
1.000 |
0.398 |
23 |
11 |
1.041 |
0.439 |
17 |
12 |
1.079 |
0.477 |
15 |
13 |
1.114 |
0.512 |
10 |
14 |
1.146 |
0.544 |
6 |
15 |
1.176 |
0.574 |
3 |
estimated from Figure 5, page 549.
Limitations:
• The method and reference ranges for LDH and CA-125 are not given. To extend these findings to other institutions, the values would have to be correlated.
Purpose: To use a scoring system based on data at presentation to predict survival in patients with advanced ovarian cancer (Stages III or IV).
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
Objective: severity, prognosis, stage
ICD-10: C56,